The QualityStocks Daily Thursday, March 7th, 2024

Today's Top 3 Investment Newsletters

Schaeffer's(LYT) $8.7000 +276.62%

360 Wall Street(IMRN) $4.5500 +175.74%

QualityStocks(MNMD) $9.0000 +51.52%

The QualityStocks Daily Stock List

Immuron Ltd (IMRN)

StockMarketWatch, MarketClub Analysis, QualityStocks, TradersPro, TraderPower, BUYINS.NET, Schaeffer's, RedChip, PennyStockScholar, Louis Navellier, The Stock Dork, PennyStockProphet, Navellier Growth, MarketBeat and 247 Market News reported earlier on Immuron Ltd (IMRN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Immuron Ltd (NASDAQ: IMRN) (ASX: IMC) (FRA: ANW) is a biopharmaceutical firm that is focused on the research, development and commercialization of polyclonal antibodies.

The firm has its headquarters in Carlton, Australia and was incorporated in 1994, on January 13th. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers around the globe, with a focus on the United States and Australia.

The company operates through the hyperimmune products and the research and development segments. The former segment is involved in Protectyn and Travelan activities which occur internationally while the latter segment is involved in research and development projects in the U.S., Israel and Australia. The company is party to a collaboration agreement with the Walter Reed Army Institute of Research, involving the development of an oral therapeutic for shigellosis. It is also party to a research agreement with the Naval Medical Research Center, entailing the development and clinical evaluation of a therapeutic which targets ETEC and Campylobacter infections.

The enterprise’s products include a formulation known as IMM-124E (Travelan), which has been developed as an antiviral for SARS-CoV-2 and is in phase 3 clinical trials to decrease the risk of contracting traveler’s diarrhea. Travelan is also an OTC medicine which helps decrease minor gastro-intestinal disorder symptoms. The enterprise also develops an immune supplement known as Protectyn, which helps maintain healthy liver and digestive function. In addition to this, it develops IMM-529, for the treatment of recurring clostridium difficile infection.

The company recently entered into a new research agreement with the U.S. Department of Defense, which will involve testing the effectiveness of its Travelan formulation in a controlled human infection model. This project expands the company’s clinical development program and is bound to have a positive impact on investments into the company.

Immuron Ltd (IMRN), closed Thursday's trading session at $4.55, up 175.7409%, on 53,777,838 volume. The average volume for the last 3 months is 842,113 and the stock's 52-week low/high is $1.481/$5.96.

Evofem Biosciences (EVFM)

MarketBeat, QualityStocks, StockMarketWatch, InvestorPlace, Schaeffer's, StockEarnings, OTC Stock Review, StocksEarning, BUYINS.NET, Profitable Trader Authority, Broad Street, MarketClub Analysis, OTCtipReporter, AllPennyStocks, PoliticsAndMyPortfolio, The Stock Dork, SmallCapVoice, The Online Investor and PennyStockScholar reported earlier on Evofem Biosciences (EVFM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Evofem Biosciences Inc. (NASDAQ: EVFM) (FRA: 1AQ1) is a commercial-stage biopharmaceutical firm which is focused on the development and commercialization of women’s healthcare products which address unmet needs in women’s reproductive and sexual health.

Evofem Biosciences Inc. has its headquarters in San Diego, California and serves consumers in the United States. The firm was founded in 2007 and is party to a collaboration agreement with the National Community Oncology Dispensing Association Inc. which entails educating the oncology community about Phexxi. Evofem Biosciences Inc. subsidiaries include Evofem Ltd., Evofem Inc. and Evofem Biosciences Operations Inc.

Evofem Biosciences Inc.’s product portfolio includes an investigational drug known as EVO100 which has been developed as an antimicrobial vaginal gel indicated for the prevention of urogenital transmission of Neisseria gonorrhoeae infection and Chlamydia trachomatis infection in women and a hormone-free vaginal gel, made up of potassium bitartrate, citric acid and lactic acid, which is indicated for the prevention of pregnancy, dubbed Phexxi. Other products developed by the company include EVO200, a vaginal gel which has been indicated for the reduction of recurrent bacterial vaginosis.

Evofem Biosciences Inc.’s national campaign, whose objective was to raise awareness of its on-demand, non-hormonal birth control method, dubbed “Get Phexxi”, achieved significant preliminary results. The continuing campaign, which is aimed at driving women to healthcare practices for Phexxi, will help advance the Phexxi uptake curve, which will not only increase sales, but also broaden their reach and boost growth.

Evofem Biosciences (EVFM), closed Thursday's trading session at $0.027, up 80%, on 4,729,988 volume. The average volume for the last 3 months is 153,565 and the stock's 52-week low/high is $0.0122/$5.00.

MoneyLion Inc. (ML)

Super Stock Picker, MarketBeat, Zacks, TradersPro, Schaeffer's, QualityStocks and FreeRealTime reported earlier on MoneyLion Inc. (ML), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MoneyLion Inc. (NYSE: ML) is a financial technology and mobile banking firm that offers a financial membership and mobile banking platform which allows individuals to take control of their finances.

The firm has its headquarters in New York and was founded in 2013 by Chee Mun Foong and Diwakar Choubey. Prior to its name change in September 2021, the firm was known as Fusion Acquisition Corp. It operates as part of the activities related to the credit mediation industry. The firm has four companies in its corporate family and serves consumers in the United States.

The company helps empower the American Dream by offering every individual access to better products for investing, saving and borrowing. It uses its machine learning-based technology and superior analytics to acquire a 360o view of every user’s personal finances, which allows them to provide uniquely personalized advice and underwriting.

The enterprise’s product platforms include Financial Heartbeat, Credit Builder Plus, Instacash Earned Income Advances, MoneyLion Investing and RoarMoney. Its Instacash platform has a 0% yearly rate advanced product that affords consumers access to their recurring income deposits. MoneyLion Investing is an online investment account which provides access to invested accounts that are separately managed, based off of model portfolios consisting of exchange-traded funds. On the other hand, its RoarMoney platform is a digital demand deposit account that has zero rewards, features and minimums.

The company recently appointed new independent directors to its Board, who each possess extensive expertise in building world-class brands, scaling businesses and engaging consumers across various platforms.

MoneyLion Inc. (ML), closed Thursday's trading session at $67.36, up 28.1827%, on 764,686 volume. The average volume for the last 3 months is 267,758 and the stock's 52-week low/high is $7.50/$70.8623.

Provectus Biopharmaceuticals (PVCT)

plrinvest, QualityStocks, Streetwise Reports, Stock News Now, Real Pennies, Investor Spec Sheet, PennyStocks24, SmarTrend Newsletters, The Street, MarketBeat, TopPennyStockMovers, Investors Underground, PennyTrader Publisher, PennyOmega, Penny Sleuth, DrStockPick, CRWEWallStreet, CRWEPicks, CRWEFinance, Club Penny Stocks Network, BestOtc, FeedBlitz, PennyToBuck, Wealth Daily, TopStockAnalysts, Wise Alerts, Seeking Alpha, Standout Stocks, StockHotTips, StreetAuthority Daily, StreetInsider, TheMicrocapNews, TheStockAdvisor, TheStockAdvisors and AllPennyStocks reported earlier on Provectus Biopharmaceuticals (PVCT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Provectus Biopharmaceuticals Inc. (OTCQB: PVCT) is a clinical-stage biotechnology firm that is focused on the development of immunotherapy medications based on halogenated xanthenes.

The firm has its headquarters in Knoxville, Tennessee and was incorporated in 2002 by Eric A. Wachter. Prior to its name change in December 2013, the firm was known as Provectus Pharmaceuticals Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The enterprise develops ethical pharmaceuticals for oncology and dermatology indications. Its pipeline is comprised of an investigational autolytic cancer immunotherapy dubbed PV-10, for gastrointestinal tumors, including hepatocellular carcinoma and adult solid tumor cancers, such as melanoma; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; colorectal cancer metastatic to the liver; and pediatric solid tumor cancers, such as Ewing sarcoma,neuroblastoma, osteosarcoma and rhabdomyosarcoma. It also develops oral formulations of cGMP RBS for the treatment of pediatric blood cancers, including leukemia; and adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers. This is in addition to developing an investigational immuno-dermatology agent dubbed PH-10, for the treatment of inflammatory dermatoses, such as atopic dermatitis and psoriasis.

The company recently expanded its research program with The Rockefeller University, which involves investigating the potential for PH-10 in treating inflammatory skin conditions. This move not only opens the company up to new growth opportunities but also brings it one step closer to getting its PH-10 candidate approved.

Provectus Biopharmaceuticals (PVCT), closed Thursday's trading session at $0.2132, up 25.4118%, on 1,884,104 volume. The average volume for the last 3 months is 1.761M and the stock's 52-week low/high is $0.056/$0.2189.

Tracon Pharmaceuticals (TCON)

MarketBeat, StockMarketWatch, BUYINS.NET, MarketClub Analysis, QualityStocks, TradersPro, TraderPower, Marketbeat.com, 360 Wall Street, Darth Trader, INO.com Market Report, Investing Futures, Market Authority, The Stock Psycho, Wall Street Mover, Money Morning, InsiderTrades, PoliticsAndMyPortfolio, The Street, The Online Investor, Broad Street and Investors Alley reported earlier on Tracon Pharmaceuticals (TCON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tracon Pharmaceuticals Inc. (NASDAQ: TCON) is a biopharmaceutical firm that is engaged in developing and commercializing therapies for cancer.

The firm has its headquarters in San Diego, California and was incorporated in October 2004. Prior to its name change in March 2005, the firm was known as Lexington Pharmaceuticals Inc. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in the United States.

The company is party to license and collaboration agreements with Case Western Reserve University to develop TRC102; I-Mab Biopharma, to develop CD73 antibody TJ004309; Jiangsu Alphamab Biopharmaceuticals Co. Ltd to develop envafolimab; and 3D Medicines Co. Ltd. It is also party to a development agreement with the National Cancer Institute.

The enterprise’s clinical-stage products include a CD73 antibody dubbed TJ004309, which is in phase I clinical development and has been developed to treat solid tumors; a small molecule known as TRC102, which is undergoing phase1 clinical trials for the treatment of glioblastoma, lung cancer, lymphomas and solid tumors and phase 2 clinical trials evaluating its effectiveness in treating mesothelioma. It is also developing YH001 for the treatment of a range of cancer indications and envafolimab, to treat soft tissue sarcoma.

The firm recently announced its latest financial results and remains focused on advancing its product candidates. The success and approval of these formulations will not only benefit patients with certain indications but also bring in additional revenues as well as investors into the firm, which will be good for its growth.

Tracon Pharmaceuticals (TCON), closed Thursday's trading session at $0.2325, up 18.0203%, on 7,028,329 volume. The average volume for the last 3 months is 78,888 and the stock's 52-week low/high is $0.1255/$2.19.

GSE Systems, Inc. (GVP)

SmarTrend Newsletters, Wall Street Resources, StockMarketWatch, QualityStocks, StreetInsider, StockOodles, PennyOmega, MarketBeat, SmallCapVoice, BestOtc, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, Marketbeat.com, PennyToBuck, StockHotTips, StreetAuthority Daily, MicroCap Gems, The Street, Barchart, Wealth Daily, Zacks, Stock Spike and Timothy Sykes reported earlier on GSE Systems, Inc. (GVP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GSE Systems, Inc. (NASDAQ: GVP) (FRA: GSE) is focused on the provision of staffing services, technical and professional engineering and simulation software to the process and power industries in various countries around the globe.

The firm has its headquarters in Columbia, Maryland and was incorporated in 1994, on March 30th. It is party to a strategic collaboration with ABB Bailey Japan Ltd which entails the provision of process simulation solutions for its Nikonkai LNG terminal in Niigata, Japan. The firm serves consumers across the globe, with a primary focus on Europe, Asia and the United States.

The company operates through the nuclear industry training and consulting, and the performance improvement solutions segments. The former segment provides project managers, technical engineers, procedure writers, planners, nuclear operations instructors, work management specialists training materials developed for the nuclear power industry. On the other hand, the latter segment is engaged in the provision of engineering services and operation training systems for the fossil fuel and nuclear power generation and process industries, as well as simulation products, which include interactive computer-based tutorials/simulations, power plant thermal performance optimization and power plant high-fidelity simulation solutions.

The enterprise markets its services and products through strategic alliance partners, representatives and agents and its network of direct sales staff. Its products are used in the metals, power generation, pharmaceutical, petroleum refining, food and beverage and specialty chemical industries.

The firm was recently awarded a contract to deliver a web-based thermal system monitoring program by a huge U.S. nuclear power plant operator. This contract will not only bring in additional revenue into the firm but may also help extend its consumer reach, which will be good for investments.

GSE Systems, Inc. (GVP), closed Thursday's trading session at $2.31, up 15.5%, on 107,545 volume. The average volume for the last 3 months is 62,469 and the stock's 52-week low/high is $1.21/$11.30.

TuanChe (TC)

SmarTrend Newsletters, StreetAuthority Daily, QualityStocks, MarketClub Analysis, ProfitableTrading, The Street, StocksEarning, StockMarketWatch, Profit Confidential, Dividend Opportunities, Investor Update, MarketBeat, Money Morning, PoliticsAndMyPortfolio, Super Stock Picker, TradersPro, StreetInsider, TopStockAnalysts, Zacks, MonsterStocksPicks, Hit and Run Candle Sticks, Investor Guide, Wall Street Resources, PennyStockCrowd, Stocks That Move, Penny Stock Rumble, Schaeffer's, Stock Stars, AllPennyStocks, TradingMarkets and MicroCap Gems reported earlier on TuanChe (TC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TuanChe Limited (NASDAQ: TC) is an omni-channel automotive marketplace that is focused on car trading activities.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2010 by Jian Chen Sun and Wei Wen. It serves consumers across the globe and is party to a limited partnership with Beijing Easyhome Furnishing Chain Group Co. Ltd, which entails the joint establishment of a retail experience which combines automotive services with home decoration products.

The company operates through the group-purchase facilitation and auto shows segments. The auto show segment comprises of the following phases, namely event execution, event planning, event request initiation and annual planning. It organizes auto shows that attract consumers and offers integrated marketing solutions to industry consumers, including automotive service providers, secondary dealers, franchised dealerships and automakers.

The enterprise also offers virtual dealership services by connecting franchised dealerships and automakers with secondary dealerships by providing services conventionally undertaken by franchised dealerships without establishing a permanent physical presence. This is in addition to enabling interactions between participants on both sides of possible transactions. Its online platforms include its tuanche.com, WeChat mini-program and its official WeChat account. The enterprise also provides consulting services, as well as business and technical support services.

The firm announced its financial results for its first quarter of 2021, which show an increase in net revenues and gross profits. It is focused on entering into strategic partnerships, having recently entered into one with China Association of Automobile Manufacturers, which will positively impact the firm’s growth, as well as bring in more investors.

TuanChe (TC), closed Thursday's trading session at $2, up 12.3596%, on 196,877 volume. The average volume for the last 3 months is 6,451 and the stock's 52-week low/high is $1.7001/$15.75.

Zhejiang Expressway (ZHEXF)

MarketBeat reported earlier on Zhejiang Expressway (ZHEXF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Zhejiang Expressway Company Limited (OTC: ZHEXF) (HKG: 0576) (FRA: ZHJ) is an investment holding firm focused on designing, constructing, operating, maintaining and managing roads in China.

The firm has its headquarters in Hangzhou, China and was incorporated in 1997, on March 1st as an infrastructure company of the Zhejiang Provincial Government for investing in, developing and operating expressways and Class 1 roads in Zhejiang Province. It operates as part of the infrastructure operations industry, under the industrials sector. The firm serves consumers in the People’s Republic of China.

The enterprise operates through the Toll Operation, Others, and Securities Operation business segments. The Toll Operation segment covers the operation and management of high-grade roads and the collection of the expressway tolls. The Securities Operation segment refers to the securities broking, margin financing and securities lending, securities underwriting and sponsorship, asset management, advisory services, and proprietary trading. The Others segment handles properties development, hotel operation, and other ancillary services. In addition to this, the enterprise provides vehicle towing, repair and emergency, and rescue services, as well as investment management and advisory services. It operates as a subsidiary of Zhejiang Communications Investment Group Company Limited.

The company, which recently released its latest financial results showing increases in its overall revenues and significant year-on-year growth for toll revenues, remains focused on expanding its main businesses scale, enhancing its core competitiveness, and growing its financial and securities business so as to increase its profit contribution to the Group. It remains committed to seizing sound investment opportunities to acquire new projects, and striving to develop into an international investment holdings company.

Zhejiang Expressway (ZHEXF), closed Thursday's trading session at $0.76982, even for the day. The average volume for the last 3 months is 1.417M and the stock's 52-week low/high is $0.59/$0.87545.

Mind Medicine Inc. (MNMD)

QualityStocks, InvestorPlace, Schaeffer's, MarketBeat, The Wealth Report, The Street, The Stock Dork, MarketClub Analysis, Daily Trade Alert, Wealth Daily, Trades Of The Day and PsychedelicNewsWire reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Research has shown that psychedelics may be useful in the treatment of a range of mental-health conditions, including anxiety, depression and post-traumatic stress disorder. Now, Okanagan researchers are looking into whether psychedelics can help manage alcoholism.

Okanagan Clinical Trials is among other sites in Finland and Canada taking part in this research. The researchers’ objective is to evaluate the effectiveness of psilocybin in treating alcohol use disorder. Psilocybin is the active ingredient found in hallucinogenic mushrooms.

To participate in the trial, all volunteers go through screening after which they participate in  10 therapy sessions, with two of sessions including the administration of 25 mg doses of synthetic psilocybin. Because it’s a randomized study, some patients may receive a placebo during the two sessions.

In a recent interview, trial coordinator Ethan Klukas stated that the 25 mg dose was fairly large. He explained that if an individual received this dose, they entered an altered state for an estimated six to eight hours.

Patients who receive the psychedelic aren’t left to experience the trip alone. They are monitored by therapists who stay in the room with them to help if any symptoms of anxiety come up. During the psychedelic “trip,” the volunteers all listen to a preselected playlist and focus on going inward. After their dosing sessions, individuals can discuss their experience with therapists and explore how it is linked to their goals around alcohol use.

Once the 10-week trial period ends, participants will be observed for an additional three months, during which their consumption of alcohol will be tracked and then compared to consumption prior to therapy.

For the study, which started in August 2022, 160 patients will be needed. The door for recruitment closes in April of this year, but until then, more volunteers are welcome. Generally, volunteers must be healthy and between 19 and 70 years of age. Additionally, they must have received a diagnosis of alcohol use disorder, ranging from moderate to severe cases.

Those interested are directed to visit https://okanaganclinicaltrials.com/

This research is sponsored by Clairvoyant Therapeutic Inc., a biotechnology company based in Vancouver. CEO Damian Kettlewell stated that the company’s objective was to become the first company globally to acquire regulatory approval for the clinical use of psilocybin in treating alcohol use disorder.

With many start-ups such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) racing to bring to market various regulator-approved psychedelic treatments, we can expect the range of ailments that these substances can effectively treat to increase over the coming years.

Mind Medicine Inc. (MNMD), closed Thursday's trading session at $9, up 51.5152%, on 38,105,521 volume. The average volume for the last 3 months is 20.979M and the stock's 52-week low/high is $2.41/$11.10.

Alibaba Group Holding Ltd. (BABA)

InvestorPlace, The Street, Kiplinger Today, Schaeffer's, MarketClub Analysis, Money Morning, Zacks, StreetInsider, Trades Of The Day, Daily Trade Alert, Marketbeat, Market Intelligence Center Alert, StocksEarning, Investopedia, The Online Investor, Wealth Insider Alert, StreetAuthority Daily, ProfitableTrading, CustomerService, Marketbeat.com, TopStockAnalysts, Louis Navellier, Uncommon Wisdom, Early Bird, GorillaTrades, CNBC Breaking News, Cabot Wealth, Top Pros' Top Picks, StockEarnings, Profit Confidential, TipRanks, The Wealth Report, AllPennyStocks, Options Elite, Investors Alley, Total Wealth, INO.com Market Report, Money and Markets, Daily Profit, Street Insider, The Street Report, Barchart, Wyatt Investment Research, SmallCapVoice, StrategicTechInvestor, Investing Daily, Market Intelligence Center, Insider Wealth Alert, Daily Wealth, Average Joe Options, Power Profit Trades, Trade of the Week, Investing Signal, MarketTamer, INO Market Report, WStreet Market Commentary, QualityStocks, Wealth Daily, Wall Street Daily, BUYINS.NET, Trader Prep, Trading Concepts, The Best Newsletters, Short Term Wealth, MarketWatch, 24/7 Trader, Inside Investing Daily, Dynamic Wealth Report, Rick Saddler, InvestmentHouse, Visual Capitalist, TheOptionSpecialist, FreeRealTime, Energy and Capital, Investing Lab, Investment U, Investing Futures, MarketArmor.com, The Weekly Options Trader, OptionAlarm News, Wealthpire Inc., SureMoney, Agora Financial, Daily Dividends, InvestorsHQ, Financial Freedom Post, Equities.com, 24-7 Stock Alert, wyatt research newsletter, Energy & Resources Digest, Atomic Pennies, Eagle Financial Publications, Beat The Street, Dividend Opportunities, Direction Alerts, ChineseWire, wealthmintrplus, Wallstreet Journal, Weekly Wizards, The Growth Stock Wire, Navellier Growth, Rockwell Trading, Shah's Insights & Indictments, SmallCapNetwork, Stock Gumshoe, StockMarketWatch, Summa Money, Market Authority, Liberty Through Wealth, Kiplinger’s Weekly Update, Terry's Tips, Inside Trading, InvestorsObserver Team, Goldman Small Cap Research, InvestorGuide, Investor Guide, The Night Owl, Investment House, Investiv, The Stock Dork, Profits Run, The Trading Report, MarketDeal, TheoTrade, Hit and Run Candle Sticks, Greenbackers and Jim Cramer reported earlier on Alibaba Group Holding Ltd. (BABA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

With competition in the Chinese cloud-computing space heating up, Alibaba Group Holding Ltd. (NYSE: BABA) is the latest major player to announce price cuts for several of its core cloud-computing products. The company’s cloud-computing unit says it is cutting prices by up to 55% for more than 100 of its core products, the largest price cut in the company’s history.

Many experts say the latest round of price cuts will reduce the cost of accessing enterprise cloud services, expanding access to the cloud market and boosting cloud development. According to company management, Alibaba’s price cuts are aimed at increasing inclusivity in the cloud-services market in the artificial intelligence era and integrating cloud computing into “all walks of life.”

Alibaba cut prices by an average of 20% on more than 100 cloud products including database, storage and computing. Alibaba Cloud Intelligence president of public cloud business Liu Weiguang noted that Alibaba is the largest cloud-service provider in the country as well as the Asia-Pacific region.

As such, the company cut prices across the board to expand access to its cloud services among both developers and enterprises. This will in turn allow developers and enterprises to benefit from cloud computing and speed up the adoption of advanced public-cloud services in various Chinese industries, Weiguang said.

Businesses in the country will require robust, cost-effective and high-performance computing power to deal with the rapid build-up of nigh-infinite amounts of data in China. Artificial intelligence (AI) tools will likely have a major role in processing this data and converting it into actionable information, but they typically require massive amounts of computing power. Cloud computing services will most likely be a godsend for startups or established companies that can’t afford to buy, install and run the computing power they need for AI tools.

Alibaba’s price cuts indicate Alibaba Group Holding Ltd’s commitment to encouraging artificial intelligence adoption and providing the support the nascent AI sector needs to evolve even faster. Given the company’s dominance of the Chinese cloud-computing space, its price cuts will have a notable effect on the market, said Charlie Dai, vice president and principal analyst at research company Forrester.

The move will likely encourage the adoption of cloud services among small and medium enterprises, Dai noted, and drive the adoption of next-generation AI tools. This would, in turn, trigger another round of price cuts among cloud-service providers looking to gain more customers and maintain their growth momentum.

Alibaba Group Holding Ltd. (BABA), closed Thursday's trading session at $72.54, off by 1.5873%, on 12,374,675 volume. The average volume for the last 3 months is 447,658 and the stock's 52-week low/high is $66.63/$105.05.

Verano Holdings Corp. (VRNOF)

QualityStocks, MarketBeat, InvestorPlace, The Street and Early Bird reported earlier on Verano Holdings Corp. (VRNOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

South Dakota is one of the top hemp growers in the country. Now, a proposed measure intended to clamp down on products that contain high THC content and other cannabinoids may threaten this burgeoning CBD market. Last week, the state’s Senate regressed to a restrictive version of HB 1125, which had been amended previously.

The amendments included in the measure that was approved by the House would have banned only products with synthetically processed, high-concentration compounds made from hemp. It would not have banned CBD and other extracts containing small amounts of cannabinoids that naturally occur in hemp flowers, such as delta-8 THC.

By widening the restrictions, the Senate may have put these products at risk. The Senate version of this measure targets vape pens, gummies, smokable flower and pre-rolled joints that are made from the hemp plant. These products flooded markets across the United States, including South Dakota, following the federal legalization of hemp under the 2018 Farm Bill.

Senator Ryan Maher explained that a full ban on these products could cause products to proliferate the state’s market this spring as retailers work to clear their inventory of flower-based hemp goods that may soon be illegal. This includes intoxicating cannabinoids such as THCP, HHC, THC-O and delta-10 THC.

Following HB 1125’s passage at the Senate, the proposed legislation was forwarded to a conference committee to reconcile it with the House version before it is presented to the governor for signing.

Governor.Kristy Noem has historically been in favor of tight restrictions, so it is expected that she will sign this measure.

Figures show that hemp farmers in the state dedicated no more than 35 acres to production of CBD flower in 2021, with the majority of their acreage serving fiber and grain crops. The South Dakota Industrial Hemp Association conducted an analysis which found that in 2022, the state was the second-largest grower, with harvests reaching 2,540 acres. That year, farmers also harvested all their hemp crop. Additionally, the state’s department of Agriculture and Natural Resources reported that in the same year, the number of hemp producers reached 40.

In 2023, South Dakota, Idaho and Montana were the major producers of both grain and fiber, making up almost one-half of America’s total fiber acreage. Final figures on production are yet to be released by the federal agriculture department.

With South Dakota standing out as one of the states that haven’t legalized adult-use marijuana, this clamp down on hemp products could spur activists to renew their push to end prohibition and license companies that are similar to Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) so that residents can have access to a diverse array of products designed to meet their different needs.

Verano Holdings Corp. (VRNOF), closed Thursday's trading session at $4.54, off by 1.9438%, on 403,973 volume. The average volume for the last 3 months is 245,190 and the stock's 52-week low/high is $2.53/$7.08.

Innovative Industrial Properties Inc. (IIPR)

InvestorPlace, Kiplinger Today, Top Pros' Top Picks, The Online Investor, Schaeffer's, QualityStocks, Daily Trade Alert, The Street, MarketBeat, Wealth Insider Alert, Trades Of The Day, DividendStocks, The Wealth Report, Zacks, TradersPro, StreetInsider, Stock Up Featured, FreeRealTime, StockMarketWatch, Stock Gumshoe, CFN Media Group, The Street Report, Investopedia, Trading Concepts, Early Bird, Outsider Club, Marketbeat.com, TipRanks, VectorVest, Wealth Daily and StreetAuthority Daily reported earlier on Innovative Industrial Properties Inc. (IIPR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Leading U.S. veterans’ organizations are urging the Biden administration to promptly relax federal marijuana laws, aligning with a growing chorus of voices advocating for rescheduling the substance six months after a recommendation from the U.S. Department of Health and Human Services (HHS). Expressing their sentiments in a recent letter, the groups have called upon the Department of Justice, which oversees the U.S. Drug Enforcement Administration (DEA), to take swift action.

Highlighting the challenges faced by veterans of the United States Armed Forces when they return home, the coalition, comprising entities such as the Minority Veterans of America, AMVETS, Iraq and Afghanistan Veterans of America, the American GI Forum, the Blinded Veterans Association and the American Legion, emphasized the importance of offering a broad spectrum of treatments to address both visible and invisible war wounds.

Currently categorized as a Schedule I drug, alongside drugs such as heroin, marijuana is deemed to have a high potential for misuse and no known medical uses. The HHS has recommended moving it to Schedule III, a significantly less-restrictive classification.

In October 2022, President Joseph Biden initiated a review of the federal cannabis policy, and insiders anticipate a formal decision from the DEA imminently, possibly within the upcoming weeks.

Although the Veterans Affairs (VA) Department isn’t allowed to refuse medical care to veterans who use cannabis in states where it is legal, the agency doesn’t cover prescriptions or offer medical cannabis as a treatment. Last year, a joint recommendation from the Defense Department and the VA advised against cannabis use for PTSD.

However, the veterans’ coalition argues that their members need this option, pointing to an American Legion survey where 82% of participants expressed a preference for federally approved medical marijuana treatment. The coalition underscored that without DEA action, many veterans are reluctant to discuss marijuana use with their VA clinicians, fearing repercussions.

Acknowledging the lengthy administrative scheduling procedure, the groups stressed the advantages of the DEA’s quick reclassification, which could include incorporation into the VHA, the biggest healthcare system in the nation.

Their appeal coincides with mounting Congressional efforts to reform federal marijuana policies. Bipartisan lawmakers from both chambers have proposed numerous bills related to cannabis and veterans, such as enabling VA providers to prescribe medical cannabis in legalized states and mandating marijuana studies on veterans with PTSD and chronic pain.

Public opinion increasingly favors cannabis legalization as well, as evidenced by a Gallup survey indicating that 70% of U.S. adults support it, including a significant number of younger voters and most Republicans.

A cohort of Democrats, led by Chuck Schumer, the Senate Majority Leader, recently pushed the DEA to take marijuana off of scheduling entirely, highlighting this as a once-in-a-decade opportunity for the Biden administration to take action.

Any change to the classification of cannabis at the federal level is likely to result in some improved regulatory environment for cannabis companies and ancillary businesses such as Innovative Industrial Properties Inc. (NYSE: IIPR) as the red tape that goes with this industry can be stifling at times.

Innovative Industrial Properties Inc. (IIPR), closed Thursday's trading session at $96.58, off by 0.134422%, on 192,925 volume. The average volume for the last 3 months is 1.541M and the stock's 52-week low/high is $63.3587/$105.07.

The QualityStocks Company Corner

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, is now in full compliance with all Nasdaq continued listing requirements and will continue to be listed and traded on the Nasdaq Capital Market. On Mar. 6, 2024, Mullen received formal notice from the Nasdaq Stock Market LLC confirming that the company has regained compliance with the annual shareholder meeting requirements set for in Nasdaq Listing Rule 5620(a). The company had previously announced on Jan. 24, 2024, that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The company anticipates being removed from Nasdaq's list of noncompliant companies within approximately four business days from the Mar. 6 receipt of Nasdaq's notification of compliance.

To view the full press release, visit https://ibn.fm/EgkyH

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $6.77, up 6.6142%, on 1,045,452 volume. The average volume for the last 3 months is 285,128 and the stock's 52-week low/high is $6.20/$5168.25.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization ("CRO") to perform the company's second DehydraTECH-powered glucagon-like peptide 1 ("GLP-1") human pilot study #2. According to the announcement, the study will be a randomized, crossover, placebo-controlled investigation that will compare three formulations, each at a 7 mg semaglutide dose: a positive control Rybelsus(R) swallowed tablet; DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. "DehydraTECH has previously shown an ability to improve delivery of certain drugs destined for the bloodstream, through the buccal/sublingual tissues of the mouth and throat," said Chris Bunka, CEO of Lexaria. "If this new study is successful in demonstrating efficacy and safety, the potential for a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets could be within reach."

To view the full press release, visit https://ibn.fm/GlFGq

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $5, up 11.6071%, on 1,417,821 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $5168.25/$.

Recent News

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has received notification that two of its patents covering core vectorelectrocardiography ("VECG") have been awarded by the United States Patent and Trademark Office. The two new patents bring the total of issued patents in HeartBeam's portfolio to 14, with four international patents as well; the company also has 20 pending patent applications worldwide. HeartBeam's VECG technology collects 3D signals of the heart and converts them into a 12-lead ECG. The first awarded patent, "Mobile three-lead cardiac monitoring device and method for automated diagnostics," covers apparatuses and methods that facilitate the comparison of cardiac signals over time for the automated or assisted detection of heart attacks, or acute myocardial infarction ("AMI").

The second patent, "Apparatus for generating an electrocardiogram" covers methods and apparatuses around HeartBeam's wrist-based ECG system, is related to HeartBeam's watch concept, which features a continuous ECG monitor with the ability to take a high sensitivity 12-lead ECG, combined in a single device that can be worn on the wrist. "HeartBeam's core VECG technology is designed to be used with portable, patient-friendly devices such as a credit-card sized system, an extended wear patch, or watch to enable physicians to monitor patients and identify cardiac health trends outside of a medical facility," said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. "These new patents reinforce our strategic vision which is founded on developing and protecting our novel VECG technology and product pipeline as we work to transform how cardiac care is delivered in the future."

To view the full press release, visit https://ibn.fm/w9fBb

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Thursday's trading session at $2.05, up 26.5432%, on 2,441,429 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.06/$3.74.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., will be represented at this month's annual Roth Conference. The conference will be held March 18–19, 2024, in Dana Point, California. According to the announcement, company officials are scheduled to present a fireside chat, slated to begin at 8 a.m. PST on March 18, 2024. Clene focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"). An archived version of the presentation will be available following the webcast on the company website.

To view the webcast, visit https://ibn.fm/af6wL

To view the full press release, visit https://ibn.fm/07QHq

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $0.4065, up 2.9114%, on 375,572 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.25/$1.44.

Recent News

Bravo Multinational Inc. (OTC: BRVO)

The QualityStocks Daily Newsletter would like to spotlightFathom Bravo Multinational Inc. (OTC: BRVO).

Bravo, in February 2024, entered an Asset Purchase Agreement to acquire certain assets of Streaming TVEE Inc. in a deal worth $9.76 million

Bravo and Pythia Experiences LLC entered an LOI to form a new company in January 2024, with Pythia owning 51%, Bravo owning 49%, Pythia contributing Vidgo Inc. and Bravo contributing a streaming platform

In September 2023, the company announced it would develop an advertising-based video streaming service and app

In June 2023, Bravo announced a strategic rebrand, positioning it for growth with a newly defined mission as an entertainment, hospitality and technology company

The company in May 2023 appointed entertainment industry figures Grant Cramer and Frank Hagan as CEO and President, respectively

Bravo Multinational (OTC: BRVO) actively explores opportunities in the entertainment, hospitality and technology sectors to generate long-term value for its shareholders through high-growth business ventures. Currently focused on pioneering innovative solutions in the digital content landscape, the company's goal is to provide cutting-edge and diverse content experiences to a global audience.

Bravo Multinational Inc. (OTC: BRVO) actively explores opportunities in the entertainment, hospitality and technology sectors to generate long-term value for its shareholders through high-growth business ventures. Currently focused on pioneering innovative solutions in the digital content landscape, the company’s goal is to provide cutting-edge and diverse content experiences to a global audience.

In February 2024, Bravo finalized a deal to acquire Streaming TVEE Inc.’s assets, marking a pivotal step in establishing its flagship offering, aptly named TVee NOW™. The acquired assets provide the company with the technology and foundation to soon offer streaming services including Video-On-Demand (VOD) and linear TV, often referred to as traditional broadcast TV, which encompasses cable and satellite networks, through a joint venture with Pythia Experiences.

TVee NOW™ plans to offer a wide range of on-demand content, including movies, series, concerts and original programming, at minimal or no cost to viewers. The service, set for beta launch in Q1 2024, will be accessible across various devices, with dedicated apps available on platforms such as Roku, Apple and Google Play stores, reinforcing Bravo’s commitment to innovation and audience accessibility.

The company is based in Virginia Beach, Virginia, with a second office soon opening in Las Vegas, Nevada.

Products

TVee NOW’s streaming service will offer a portion of its content for free, catering to the growing demographic of cord-cutters and aligning with the dynamic landscape of advertising-based video on demand (AVOD) streaming. Bravo’s Over-The-Top (OTT) streaming platform is specifically crafted to deliver content directly to viewers via the internet, accessible through a browser or freely downloadable apps on smartphones, tablets and smart TVs.

Bravo’s planned strategic approach for content is to first integrate partnered Free Ad-Supported TV (FAST) channels, programmatic advertising and a tiered revenue sharing model. Additionally, the company plans to complete the deal with Pythia Experiences, enabling a hybrid model comprised of AVOD, utilizing programmatic advertising through ad servers, and Subscription-based Video-on-Demand (SVOD), which the company plans to offer at competitive rates compared to other services. With this model completed, Bravo can bridge the gap until the company can ultimately create its own original content.

Through the asset purchase agreement with Streaming TVEE, Inc., the company obtained exclusive rights, image and likeness, label waivers and exploitation rights for streaming of 117 high-definition music and comedy performances, each offering a director’s cut and multiple camera perspectives. Some of the music artists include Snoop Dogg, H.E.R., Kings of Leon, Alicia Keys and Bone Thugs-N-Harmony, along with comedic performances from Bill Burr, Jim Gaffigan, Kristen Schaal, Rob Delaney and others. This original footage will allow Bravo to recreate shows in diverse formats, which can showcase these concert films in a compelling full-feature format.

Market Opportunity

A report from Fortune Business Insights, a global market research and reporting firm, estimated the global video streaming market at $455.45 billion in 2022. It is projected to grow from $554.33 billion in 2023 to $1.9 trillion by 2030, achieving a CAGR of 19.3% during the forecast period.

Growth drivers, according to the report, include a rising number of users of Video-on-Demand services (YouTube, for example) worldwide and the growing adoption of OTT content providers (like Netflix and Hulu, among many others) by consumers, as well as consumers’ willingness to spend more for streaming video content.

Management Team

Grant Cramer is CEO and Director of Bravo. He has more than 30 years of experience as an actor, writer, director, producer and production executive. As founder and president of Landafar Entertainment and Global Pictures Media, he has overseen development and production of 14 feature films. He executive produced Lone Survivor, November Man and Arctic Dogs. He produced And So It Goes, directed by Rob Reiner and starring Michael Douglas and Diane Keaton. His short film Say Goodnight, Michael won several awards, including the Grand Jury Award at the New York International Independent Film Festival.

Frank Hagan is Bravo’s President and Director. He is an Emmy-nominated producer with over 30 years of experience in the entertainment industry. He is the former Programming Director and GM of QTN. He has produced shows for major networks and companies, including Discovery Channel, History Channel and Relativity Media. Most recently, he served as a consulting producer for Electric Entertainment’s ElectricNOW! and the Saturn Awards and worked as a regular weekly panelist for Outlaw Internet Radio.

Richard Kaiser is CFO and Director of Bravo. He is also CFO at BioForce Nanosciences Holdings Inc. and Gold Rock Holdings Inc. He serves on the board of Element Global Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings Inc. He previously directed investor relations for Royal Standard Minerals Inc. and Scorpio Mining Inc. He was also Head of Corporate Communication and Investor Relations at Air Packaging Technologies Inc. and Puff Pack Industries Inc.

Kayla Slick is COO and Director at Bravo. She has more than 15 years of experience in various industries, including finance, healthcare, technology, retail, hospitality and entertainment. She co-founded The PRIME Symposium and significantly increased revenues for INSIDE Public Accounting. She held positions at Interactive Digital Solutions, where she founded the Sales Development Program and was later promoted to Marketing Communications Director for IDS’ flagship virtual patient observation product.

Bravo Multinational Inc. (OTC: BRVO), closed Thursday's trading session at $0.18, up 5.8824%, on 14,200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0461/$0.95.

Recent News

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0)

The QualityStocks Daily Newsletter would like to spotlight Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0).

Political controversies surrounding threats to the United States' election integrity and the international aggressions of Russia's government underscore concerns about the ever-present need to maintain the security of personal and business communications

Swiss hosted Sekur Private Data Ltd. provides a private and secure communications platform that the company is presently marketing to SMBs in the U.S. with plans to expand to other nations during the coming year

SWISF provides its encrypted data protection services under Swiss Internet protocol security laws, acknowledging that Switzerland has the strictest data privacy laws in the world

Sekur boasts a 100 percent-owned infrastructure and proprietary technology to help ensure customers' data won't be compromised by third-party operators

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0), a leading Swiss-hosted secure and private communications platform, and its offerings provide key solutions for greater online data privacy required during the current atmosphere of artificial intelligence ("AI") data harvesting. According to the company, big technology companies are accumulating huge amounts of personal data, often without users' informed consent or knowledge, to train their large language models. This can expose individuals to online privacy risk because the harvesting process might unintentionally capture sensitive information such as names, locations and opinions. In addition, data points can be analyzed by AI models to infer personal characteristics, while biases in the harvested data can lead to discriminatory outcomes. In addition, the company noted, there's always the risk of data breaches or misuse, where the harvested data could be compromised or used for purposes beyond the user's consent.

Sekur notes that while it supports innovation, it also believes that both individuals and companies should take steps to secure their data; those steps include the use of encryption, privacy tools and careful online behavior. Sekur offers several tools that also support security, including SekurRelay Enterprise Email Solution, SekurVPN and SekurMessenger. Sekur's Data privacy solutions are all hosted in Switzerland, protecting users' data from any outside data intrusion requests. "In the age of AI and big tech, our data footprints are becoming increasingly complex," said Sekur Private Data CEO Alain Ghiai in the press release. "Securing your online data and communications is no longer a choice — it's the cornerstone of safeguarding your digital identity and future whether you are an individual, a small business or a large organization. At Sekur, we strive to maintain your privacy and security above everything else."

To view the full press release, visit https://ibn.fm/uk7nQ

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at www.Sekur.com, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.

Products

Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

  • SekurMail® is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
  • SekurVPN® creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
  • SekurMessenger® is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (GDSA) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

Sekur Private Data Ltd. (OTCQB: SWISF), closed Thursday's trading session at $0.052, up 1.9608%, on 6,127 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0394/$0.1576.

Recent News

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Correlate (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform for distributed energy solutions across North America, is taking advantage of the increasing shift to renewables across various social and economic sectors as more people come to terms with the reality of climate change. "Over $1.7 trillion worldwide was estimated to be invested in technologies such as wind, solar power, electric vehicles, and batteries in 2023, by far the most ever spent on clean energy in a single year. In addition, the new attention to climate risks, as well as the associated transition to green energy, has been diverse, moving beyond power generation and heavy industry," a recent article reads. "Correlate understands this growing shift and has positioned itself as the go-to company for decentralized energy generation. Having offered its products and services to corporations such as Continental Envelope and American Tire Distributors (‘ATD'), the company has proven itself repeatedly, affirming the superiority of its products and services. As more companies recognize the challenges associated with climate change and appreciate the value of renewable energy sources, Correlate anticipates an uptick in the demand for its products and services. As such, it is confident that 2024 will be its biggest year yet."

To view the full article, visit https://ibn.fm/x3VGL

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Thursday's trading session at $1.48, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3501/$2.35.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

The tech community is buzzing with concern and speculation about the possible impact of the next iOS update by Apple on the Web3 app and crypto ecosystem in the European Union. The center of this issue lies in Apple's decision to remove progressive web apps on its devices. This initiative could significantly change the sector for users and developers alike. At first sight, the move appears to be a step forward in complying with the Digital Markets Act under the European Union. This act is focused on encouraging a more competitive digital market. It may have unforeseen consequences, however, especially for crypto and Web3 applications. This decision has been criticized by many, including NoOnes CEO Ray Yousef, who views the move as an attack against a free market for Bitcoin and information. Yousef is calling for the tech community to think about the broader implications of this policy change, noting that the time has come to boycott Apple. His appeal highlights the increasing concerns within the crypto field regarding the future of application development and distribution on major platforms. The Web3 app and crypto ecosystem is at a critical point, especially with the release date of iOS 17.4 inching closer. Given the track record of Web3 finding ways to march ahead despite the challenges in the existing regulatory landscape, it is possible that entities such as Horizon Fintex will still find a way to maintain their growth trajectory should the Apple update adversely affect any future plans they may have had.

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.

Products

Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (merj.exchange), an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News

chart

SOBRsafe Inc. (NASDAQ: SOBR)

The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, has announced a new customer: Breyta House, a sober-living facility located in Houston. The facility empowers women on their journey to recovery and overall wellness. Bretya House will initially be installing SOBRcheck(TM) for point-of-care alcohol screening. Sober-living facilities, or recovery housing, is a recovery support service specifically for those working to recover from substance-use issues. According to the announcement, there are currently an estimated 17,934 recovery homes located in the United States.

"With our ability to provide both point-of-care screening and continuous monitoring, we believe that we are uniquely positioned to support all components of behavioral health," said SOBRSafe chair and CEO Dave Gandini in the press release. "Already we have been adopted for inpatient, residential and outpatient uses, as well as for facility and practice-management software integration. We deeply align with the mission of Breyta House, and we are proud to add our advanced technology to its cutting-edge sober living model."

To view the full press release, visit https://ibn.fm/8e5Hs

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.

Products

The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.

SOBRsafe™

With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.

SOBRcheck™

SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.

SOBRsure™

SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.

 

Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Thursday's trading session at $0.592675, off by 0.683032%, on 61,694 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2004/$2.53.

Recent News

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

GEMXX (OTC: GEMZ), a mine-to-market gold, gemstone and jewelry producer with global reach, recently announced that it is anticipating strong growth over the next 24 months, founding this forecast on the sustained upward trajectory in gold prices and the burgeoning demand for ammolite jewelry. "In the press release announcing the forecast of robust growth, GEMXX describes its entry into gold mining as ‘a new and welcomed asset to the company's balance sheet,' with gold adding considerable support to its mine-to-market business model... The press release also describes the growing demand for ammolite jewelry, which has been driven by the rapidly growing recognition of ammolite as a rare gemstone. Ammolite's rarity stems from its limited availability – it is only found in southern Alberta, Canada – as well as its iridescent characteristics. GEMXX says the company has experienced additional demand throughout India and Asia, given ammolite ‘appeals to a discerning clientele seeking exclusive and collectible pieces,'" reads a recent article. "We are excited about the tremendous potential for growth in both the ammolite and gold markets," GEMXX President Richard Clowater is quoted as saying. "Our commitment to quality, craftsmanship, and our ability to adapt to market dynamics position us for sustained success. We are confident we will be able to deliver strong returns to our shareholders."

To view the full article, visit https://ibn.fm/Odrsn

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.

 

GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Thursday's trading session at $0.03343, off by 11.3263%, on 109,787 volume. The average volume for the last 3 months is 64,774 and the stock's 52-week low/high is $0.0172/$0.75.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Thursday's trading session at $0.379, up 5.2485%, on 2,222,774 volume. The average volume for the last 3 months is 220,756 and the stock's 52-week low/high is $0.2913/$2.08.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Thursday's trading session at $4.25, off by 2.968%, on 62,667 volume. The average volume for the last 3 months is 65,864 and the stock's 52-week low/high is $3.8797/$46.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.